Dianthus Therapeutics, Inc. · GETTEX:87E

Dianthus Therapeutics, Inc. financial statements

Dianthus Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.04M6.24M2.83M6.42M1.48M0000
Cost of revenue412.0K355.0K147.0K2.02M1.98M1.84M875.0K376.0K6.00K
Gross profit2.04M6.24M2.83M6.42M1.48M-1.98M-1.84M-875.0K-376.0K-6.00K
Research and development145.6M83.1M32.8M29.4M46.8M50.6M59.2M41.3M27.9M5.78M
Selling, general and administrative34.3M25.0M18.2M6.74M1.96M28.1M23.8M18.6M7.83M3.49M
Operating income-177.9M-101.9M-48.2M-29.7M-74.7M-78.7M-83.0M-60.0M-35.7M-9.27M
Depreciation and amortization111.0K96.0K67.0K1.93M2.02M1.98M1.84M875.0K376.0K6.00K
EBITDA-177.8M-101.8M-48.1M-27.8M-72.7M-76.7M-81.1M-59.1M-35.4M-9.26M
Interest expense3.56M3.77M163.0K
Income before tax-162.3M-85.0M-43.6M-28.5M-13.1M-74.9M-76.8M-57.5M-35.5M-9.43M
Income tax0000000000
Net income-162.3M-85.0M-43.6M-28.5M-71.1M-74.9M-76.8M-57.5M-35.5M-9.43M
Earnings per share, basic-4.20-2.55-8.45-32.57-1.29-1.71-2.07-3.13-19.12-65.15
Earnings per share, diluted-4.20-2.55-8.45-32.57-1.29-1.71-2.07-3.13-19.12-65.15

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents51.1M22.8M132.3M15.4M131.7M58.2M65.1M58.3M51.4M4.51M
Short-term investments353.2M252.4M41.4M60.1M45.3M90.7M80.7M84.2M
Receivables52.0K0294.0K4.70M1.48M6.25M
Inventory852.0K264.0K
Current assets409.4M280.9M177.5M82.0M180.7M151.5M149.8M145.3M52.5M10.8M
Property, plant and equipment296.0K194.0K185.0K142.0K7.46M8.31M9.89M10.2M1.96M
Total assets530.9M374.0M179.4M83.1M189.9M161.6M161.5M157.3M54.5M11.3M
Accounts payable9.72M4.58M2.61M1.17M3.04M3.76M2.81M3.49M167.0K1.67M
Current liabilities30.7M18.5M9.63M8.22M10.9M11.4M14.1M10.4M4.14M2.30M
Total debt1.39M1.49M585.0K788.0K
Total liabilities37.5M21.5M10.5M9.45M17.3M17.7M20.3M11.7M4.14M2.30M
Shareholders' equity493.4M352.5M168.9M-44.4M-17.2M143.9M141.2M145.6M-42.1M-8.87M
Shares outstanding43.2M31.1M14.8M875.3K58.8M48.5M39.3M33.3M2.35M39.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-129.1M-78.2M-36.9M-29.1M-59.5M-64.0M-57.1M-41.9M-22.3M-6.53M
Capital spending-213.0K-105.0K-110.0K-314.0K-1.26M-400.0K-3.06M-7.67M-2.20M-139.0K
Free cash flow-129.3M-78.3M-37.0M-29.4M-60.8M-64.4M-60.2M-49.6M-24.5M-6.67M
Cash from investing-122.8M-286.8M20.3M-59.8M43.4M-10.6M1.53M-91.7M-2.20M-139.0K
Cash from financing280.1M255.6M133.6M96.7M89.6M67.7M62.3M142.1M71.5M10.7M
Share buybacks317.0K-88.0K-213.0K-107.0K
Change in cash28.2M-109.4M117.0M7.79M73.5M-6.92M6.73M8.56M47.0M4.04M